Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition.
Dirk TheileJulie NillesAndreas Daniel MeidPublished in: British journal of clinical pharmacology (2023)